Climb Bio Inc., a biotechnology company focused on developing therapeutics for immune-mediated diseases, announced on May 19, 2025, the granting of an inducement equity award to a new employee under its 2025 Inducement Plan. This award, in line with Nasdaq Listing Rule 5635(c)(4), comprises a non-statutory stock option to purchase up to 120,000 shares of the company's common stock at an exercise price of $1.27 per share, matching the closing price on the grant date. The option, which has a ten-year term, vests over four years, with 25% becoming exercisable on the first anniversary of the employee's start date and the rest vesting in 36 equal monthly installments, contingent on ongoing employment.